Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib

Thorac Cancer. 2021 Mar;12(5):690-692. doi: 10.1111/1759-7714.13785. Epub 2021 Jan 12.

Abstract

Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertinib due to elevated mesenchymal epithelial transition (MET) copy number amplification. However, early-onset interstitial pneumonitis occurred within two days.

Keywords: Crizotinib; NSCLC; Osimertinib; early-onset interstitial pneumonitis.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides / pharmacology
  • Acrylamides / therapeutic use*
  • Aniline Compounds / pharmacology
  • Aniline Compounds / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / complications*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Crizotinib / pharmacology
  • Crizotinib / therapeutic use*
  • Humans
  • Lung Diseases, Interstitial / etiology*
  • Lung Diseases, Interstitial / physiopathology
  • Lung Neoplasms / complications*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged

Substances

  • Acrylamides
  • Aniline Compounds
  • osimertinib
  • Crizotinib